China has become more cutting edge in terms of innovation rather than being a fast follower and AstraZeneca PLC, the long-time commercial leader there among foreign pharma firms, is determined to partner with the country’s leading R&D pioneers, says Shaun Grady, the UK major’s head of business development operations.
AstraZeneca Likes What Chinese Innovation Has To Offer
Chinese drugmakers’ “ability to move quicker at pace and with purpose” than counterparts in the US, Europe and other parts of the world underlies increasing deal activity with big pharmas, AstraZeneca’s BD chief Shaun Grady tells Scrip.
